- Nahdi Medical reported a profit of 238.4 million riyals in the second quarter of 2025.
- There was a year-on-year decrease in profit of 3.8% compared to last year’s 247.7 million riyals.
- Revenue for the second quarter increased by 2.2% year-on-year, amounting to 2.53 billion riyals.
- Operating profit declined by 4.7% year-on-year to 260.6 million riyals.
- The company noted that the second quarter results were influenced by a stronger performance in the first quarter and a high baseline from the same period last year due to seasonal shifts.
- Market analysts have differing opinions with 4 buy ratings, 4 hold ratings, and 1 sell rating for Nahdi Medical.
A look at Nahdi Medical Co Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Nahdi Medical Co is positioned with a solid dividend score of 4, indicating a promising payout to investors. Additionally, the company shows strong momentum with a score of 5, suggesting a positive trend in its performance. While both growth and resilience scores stand at 3, reflecting moderate prospects in these areas, the value score comes in at 2. Overall, Nahdi Medical Co appears to offer a stable investment opportunity with room for growth and consistent dividends.
Nahdi Medical Company, a pharmacy services provider based in the Kingdom of Saudi Arabia, focuses on retailing prescription and over-the-counter medicines. With a balance of growth potential, financial stability, and strong dividend performance as indicated by the Smart Scores, investors may view Nahdi Medical Co as a reliable choice for long-term investment in the healthcare sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
